Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2023

Zymfentra(Infliximab-Dyyb)

Medicare prescription drug cost, prescriptions and prescribers, 2024

$213K

Medicare cost, 2024

Medicare drug plans spent $212,914 on Zymfentra (infliximab-dyyb) in 2024, for 37 prescriptions and refills filled by 14 patients. It was first approved in 2023. At about $5,754 per prescription it is a high-cost drug.

Medicare cost, 2024

$213K

Prescriptions

37

$5,754.44 per claim

Patients

14

13 prescribers

Total spending, 2024

$222K

$14,802.47 per patient

Questions and answers

How much does Medicare spend on Zymfentra?

Medicare prescription drug plans paid $213K for Zymfentra in 2024, for 37 prescriptions and refills to 14 patients. The average cost per claim was $5,754.44.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Prescriber data by year

YearPrescribersClaimsPatientsCost
2024133714$213K

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Celltrion USA,39$222K

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
13
RxNorm concept IDs
2675742, 2675749, 2675753, 2675757, 797544
Application numbers
BLA761358

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube